PubMed:32979436 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":863,"end":870},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T2","span":{"begin":863,"end":870},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"},{"id":"T3","span":{"begin":1007,"end":1014},"obj":"https://glytoucan.org/Structures/Glycans/G00021MO"},{"id":"T4","span":{"begin":1007,"end":1014},"obj":"https://glytoucan.org/Structures/Glycans/G54161DR"}],"text":"The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.\nThe SARS-CoV-2 spike glycoproteins (SGPs) and human angiotensin converting enzyme 2 (ACE2) are the two key targets for the prevention and treatment of COVID-19. Host cell surface heparan sulfate (HS) is believed to interact with SARS-CoV-2 SGPs to facilitate host cell entry. In the current study, a series of polysaccharides from Saccharina japonica were prepared to investigate the structure-activity relationship on the binding abilities of polysaccharides (oligosaccharides) to pseudotype particles, including SARS-CoV-2 SGPs, and ACE2 using surface plasmon resonance. Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) displayed strongly inhibited interaction between SARS-CoV-2 SGPs and heparin while showing negligible inhibition of the interaction between SARS-CoV-2 SGPs and ACE2. The IC50 values of SJ-D-S-H and Gn in blocking heparin SGP binding were 27 and 231 nM, respectively. NMR analysis showed that the structure of SJ-D-S-H featured with a backbone of 1, 3-linked α-L-Fucp residues sulfated at C4 and C2/C4 and 1, 3-linked α-L-Fucp residues sulfated at C4 and branched with 1, 6-linked β-D-galacto-biose; Gn had a backbone of alternating 1, 4-linked β-D-GlcAp residues and 1, 2-linked α-D-Manp residues. The sulfated galactofucan and glucuronomannan showed strong binding ability to SARS-CoV-2 SGPs, suggesting that these polysaccharides might be good candidates for preventing and/or treating SARS-CoV-2."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":76,"end":89},"obj":"Body_part"},{"id":"T2","span":{"begin":184,"end":197},"obj":"Body_part"},{"id":"T3","span":{"begin":329,"end":341},"obj":"Body_part"},{"id":"T4","span":{"begin":329,"end":333},"obj":"Body_part"},{"id":"T5","span":{"begin":342,"end":357},"obj":"Body_part"},{"id":"T6","span":{"begin":359,"end":361},"obj":"Body_part"},{"id":"T7","span":{"begin":427,"end":431},"obj":"Body_part"},{"id":"T8","span":{"begin":473,"end":488},"obj":"Body_part"},{"id":"T9","span":{"begin":607,"end":622},"obj":"Body_part"},{"id":"T10","span":{"begin":624,"end":640},"obj":"Body_part"},{"id":"T11","span":{"begin":863,"end":870},"obj":"Body_part"},{"id":"T12","span":{"begin":1007,"end":1014},"obj":"Body_part"},{"id":"T13","span":{"begin":1128,"end":1136},"obj":"Body_part"},{"id":"T14","span":{"begin":1302,"end":1310},"obj":"Body_part"},{"id":"T15","span":{"begin":1510,"end":1525},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma67653"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma63023"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma63023"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma82746"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma82746"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma82742"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma13478"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma13478"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma82746"}],"text":"The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.\nThe SARS-CoV-2 spike glycoproteins (SGPs) and human angiotensin converting enzyme 2 (ACE2) are the two key targets for the prevention and treatment of COVID-19. Host cell surface heparan sulfate (HS) is believed to interact with SARS-CoV-2 SGPs to facilitate host cell entry. In the current study, a series of polysaccharides from Saccharina japonica were prepared to investigate the structure-activity relationship on the binding abilities of polysaccharides (oligosaccharides) to pseudotype particles, including SARS-CoV-2 SGPs, and ACE2 using surface plasmon resonance. Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) displayed strongly inhibited interaction between SARS-CoV-2 SGPs and heparin while showing negligible inhibition of the interaction between SARS-CoV-2 SGPs and ACE2. The IC50 values of SJ-D-S-H and Gn in blocking heparin SGP binding were 27 and 231 nM, respectively. NMR analysis showed that the structure of SJ-D-S-H featured with a backbone of 1, 3-linked α-L-Fucp residues sulfated at C4 and C2/C4 and 1, 3-linked α-L-Fucp residues sulfated at C4 and branched with 1, 6-linked β-D-galacto-biose; Gn had a backbone of alternating 1, 4-linked β-D-GlcAp residues and 1, 2-linked α-D-Manp residues. The sulfated galactofucan and glucuronomannan showed strong binding ability to SARS-CoV-2 SGPs, suggesting that these polysaccharides might be good candidates for preventing and/or treating SARS-CoV-2."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":59,"end":67},"obj":"Disease"},{"id":"T2","span":{"begin":167,"end":175},"obj":"Disease"},{"id":"T3","span":{"begin":314,"end":322},"obj":"Disease"},{"id":"T4","span":{"begin":392,"end":400},"obj":"Disease"},{"id":"T5","span":{"begin":677,"end":685},"obj":"Disease"},{"id":"T6","span":{"begin":843,"end":851},"obj":"Disease"},{"id":"T7","span":{"begin":934,"end":942},"obj":"Disease"},{"id":"T8","span":{"begin":1471,"end":1479},"obj":"Disease"},{"id":"T9","span":{"begin":1582,"end":1590},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.\nThe SARS-CoV-2 spike glycoproteins (SGPs) and human angiotensin converting enzyme 2 (ACE2) are the two key targets for the prevention and treatment of COVID-19. Host cell surface heparan sulfate (HS) is believed to interact with SARS-CoV-2 SGPs to facilitate host cell entry. In the current study, a series of polysaccharides from Saccharina japonica were prepared to investigate the structure-activity relationship on the binding abilities of polysaccharides (oligosaccharides) to pseudotype particles, including SARS-CoV-2 SGPs, and ACE2 using surface plasmon resonance. Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) displayed strongly inhibited interaction between SARS-CoV-2 SGPs and heparin while showing negligible inhibition of the interaction between SARS-CoV-2 SGPs and ACE2. The IC50 values of SJ-D-S-H and Gn in blocking heparin SGP binding were 27 and 231 nM, respectively. NMR analysis showed that the structure of SJ-D-S-H featured with a backbone of 1, 3-linked α-L-Fucp residues sulfated at C4 and C2/C4 and 1, 3-linked α-L-Fucp residues sulfated at C4 and branched with 1, 6-linked β-D-galacto-biose; Gn had a backbone of alternating 1, 4-linked β-D-GlcAp residues and 1, 2-linked α-D-Manp residues. The sulfated galactofucan and glucuronomannan showed strong binding ability to SARS-CoV-2 SGPs, suggesting that these polysaccharides might be good candidates for preventing and/or treating SARS-CoV-2."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":14,"end":22},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T2","span":{"begin":209,"end":214},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T3","span":{"begin":329,"end":333},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T4","span":{"begin":427,"end":431},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T5","span":{"begin":461,"end":462},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T6","span":{"begin":557,"end":565},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T7","span":{"begin":1032,"end":1034},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T8","span":{"begin":1126,"end":1127},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":1182,"end":1184},"obj":"http://purl.obolibrary.org/obo/CLO_0037284"},{"id":"T10","span":{"begin":1189,"end":1191},"obj":"http://purl.obolibrary.org/obo/CLO_0002105"},{"id":"T11","span":{"begin":1189,"end":1191},"obj":"http://purl.obolibrary.org/obo/CLO_0051742"},{"id":"T12","span":{"begin":1192,"end":1194},"obj":"http://purl.obolibrary.org/obo/CLO_0037284"},{"id":"T13","span":{"begin":1241,"end":1243},"obj":"http://purl.obolibrary.org/obo/CLO_0037284"},{"id":"T14","span":{"begin":1300,"end":1301},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.\nThe SARS-CoV-2 spike glycoproteins (SGPs) and human angiotensin converting enzyme 2 (ACE2) are the two key targets for the prevention and treatment of COVID-19. Host cell surface heparan sulfate (HS) is believed to interact with SARS-CoV-2 SGPs to facilitate host cell entry. In the current study, a series of polysaccharides from Saccharina japonica were prepared to investigate the structure-activity relationship on the binding abilities of polysaccharides (oligosaccharides) to pseudotype particles, including SARS-CoV-2 SGPs, and ACE2 using surface plasmon resonance. Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) displayed strongly inhibited interaction between SARS-CoV-2 SGPs and heparin while showing negligible inhibition of the interaction between SARS-CoV-2 SGPs and ACE2. The IC50 values of SJ-D-S-H and Gn in blocking heparin SGP binding were 27 and 231 nM, respectively. NMR analysis showed that the structure of SJ-D-S-H featured with a backbone of 1, 3-linked α-L-Fucp residues sulfated at C4 and C2/C4 and 1, 3-linked α-L-Fucp residues sulfated at C4 and branched with 1, 6-linked β-D-galacto-biose; Gn had a backbone of alternating 1, 4-linked β-D-GlcAp residues and 1, 2-linked α-D-Manp residues. The sulfated galactofucan and glucuronomannan showed strong binding ability to SARS-CoV-2 SGPs, suggesting that these polysaccharides might be good candidates for preventing and/or treating SARS-CoV-2."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":76,"end":89},"obj":"Chemical"},{"id":"T2","span":{"begin":184,"end":197},"obj":"Chemical"},{"id":"T3","span":{"begin":215,"end":226},"obj":"Chemical"},{"id":"T4","span":{"begin":342,"end":357},"obj":"Chemical"},{"id":"T5","span":{"begin":342,"end":349},"obj":"Chemical"},{"id":"T6","span":{"begin":350,"end":357},"obj":"Chemical"},{"id":"T7","span":{"begin":359,"end":361},"obj":"Chemical"},{"id":"T9","span":{"begin":473,"end":488},"obj":"Chemical"},{"id":"T10","span":{"begin":607,"end":622},"obj":"Chemical"},{"id":"T11","span":{"begin":624,"end":640},"obj":"Chemical"},{"id":"T12","span":{"begin":762,"end":765},"obj":"Chemical"},{"id":"T13","span":{"begin":863,"end":870},"obj":"Chemical"},{"id":"T14","span":{"begin":982,"end":985},"obj":"Chemical"},{"id":"T15","span":{"begin":1007,"end":1014},"obj":"Chemical"},{"id":"T16","span":{"begin":1106,"end":1109},"obj":"Chemical"},{"id":"T17","span":{"begin":1189,"end":1191},"obj":"Chemical"},{"id":"T18","span":{"begin":1510,"end":1525},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_28815"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_24500"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_16189"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_74056"},{"id":"A8","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_28815"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_50699"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_73454"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_73454"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_73454"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_30083"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"}],"text":"The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.\nThe SARS-CoV-2 spike glycoproteins (SGPs) and human angiotensin converting enzyme 2 (ACE2) are the two key targets for the prevention and treatment of COVID-19. Host cell surface heparan sulfate (HS) is believed to interact with SARS-CoV-2 SGPs to facilitate host cell entry. In the current study, a series of polysaccharides from Saccharina japonica were prepared to investigate the structure-activity relationship on the binding abilities of polysaccharides (oligosaccharides) to pseudotype particles, including SARS-CoV-2 SGPs, and ACE2 using surface plasmon resonance. Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) displayed strongly inhibited interaction between SARS-CoV-2 SGPs and heparin while showing negligible inhibition of the interaction between SARS-CoV-2 SGPs and ACE2. The IC50 values of SJ-D-S-H and Gn in blocking heparin SGP binding were 27 and 231 nM, respectively. NMR analysis showed that the structure of SJ-D-S-H featured with a backbone of 1, 3-linked α-L-Fucp residues sulfated at C4 and C2/C4 and 1, 3-linked α-L-Fucp residues sulfated at C4 and branched with 1, 6-linked β-D-galacto-biose; Gn had a backbone of alternating 1, 4-linked β-D-GlcAp residues and 1, 2-linked α-D-Manp residues. The sulfated galactofucan and glucuronomannan showed strong binding ability to SARS-CoV-2 SGPs, suggesting that these polysaccharides might be good candidates for preventing and/or treating SARS-CoV-2."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":342,"end":357},"obj":"GlycoEpitope"},{"id":"T2","span":{"begin":359,"end":361},"obj":"GlycoEpitope"}],"attributes":[{"id":"A1","pred":"glyco_epitope_db_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0086"},{"id":"A2","pred":"glyco_epitope_db_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/EP0086"}],"text":"The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.\nThe SARS-CoV-2 spike glycoproteins (SGPs) and human angiotensin converting enzyme 2 (ACE2) are the two key targets for the prevention and treatment of COVID-19. Host cell surface heparan sulfate (HS) is believed to interact with SARS-CoV-2 SGPs to facilitate host cell entry. In the current study, a series of polysaccharides from Saccharina japonica were prepared to investigate the structure-activity relationship on the binding abilities of polysaccharides (oligosaccharides) to pseudotype particles, including SARS-CoV-2 SGPs, and ACE2 using surface plasmon resonance. Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) displayed strongly inhibited interaction between SARS-CoV-2 SGPs and heparin while showing negligible inhibition of the interaction between SARS-CoV-2 SGPs and ACE2. The IC50 values of SJ-D-S-H and Gn in blocking heparin SGP binding were 27 and 231 nM, respectively. NMR analysis showed that the structure of SJ-D-S-H featured with a backbone of 1, 3-linked α-L-Fucp residues sulfated at C4 and C2/C4 and 1, 3-linked α-L-Fucp residues sulfated at C4 and branched with 1, 6-linked β-D-galacto-biose; Gn had a backbone of alternating 1, 4-linked β-D-GlcAp residues and 1, 2-linked α-D-Manp residues. The sulfated galactofucan and glucuronomannan showed strong binding ability to SARS-CoV-2 SGPs, suggesting that these polysaccharides might be good candidates for preventing and/or treating SARS-CoV-2."}

{"project":"LitCovid-PubTator","denotations":[{"id":"4","span":{"begin":59,"end":69},"obj":"Species"},{"id":"5","span":{"begin":95,"end":110},"obj":"Chemical"},{"id":"6","span":{"begin":124,"end":136},"obj":"Chemical"},{"id":"7","span":{"begin":142,"end":161},"obj":"Species"},{"id":"39","span":{"begin":167,"end":177},"obj":"Species"},{"id":"40","span":{"begin":209,"end":214},"obj":"Species"},{"id":"41","span":{"begin":215,"end":246},"obj":"Gene"},{"id":"42","span":{"begin":248,"end":252},"obj":"Gene"},{"id":"43","span":{"begin":314,"end":322},"obj":"Disease"},{"id":"44","span":{"begin":342,"end":357},"obj":"Chemical"},{"id":"45","span":{"begin":359,"end":361},"obj":"Chemical"},{"id":"46","span":{"begin":392,"end":402},"obj":"Species"},{"id":"47","span":{"begin":473,"end":488},"obj":"Chemical"},{"id":"48","span":{"begin":494,"end":513},"obj":"Species"},{"id":"49","span":{"begin":607,"end":622},"obj":"Chemical"},{"id":"50","span":{"begin":624,"end":640},"obj":"Chemical"},{"id":"51","span":{"begin":677,"end":687},"obj":"Species"},{"id":"52","span":{"begin":698,"end":702},"obj":"Gene"},{"id":"53","span":{"begin":745,"end":757},"obj":"Chemical"},{"id":"54","span":{"begin":773,"end":788},"obj":"Chemical"},{"id":"55","span":{"begin":843,"end":853},"obj":"Species"},{"id":"56","span":{"begin":863,"end":870},"obj":"Chemical"},{"id":"57","span":{"begin":934,"end":944},"obj":"Species"},{"id":"58","span":{"begin":954,"end":958},"obj":"Gene"},{"id":"59","span":{"begin":1007,"end":1014},"obj":"Chemical"},{"id":"60","span":{"begin":1152,"end":1160},"obj":"Chemical"},{"id":"61","span":{"begin":1211,"end":1219},"obj":"Chemical"},{"id":"62","span":{"begin":1293,"end":1295},"obj":"Chemical"},{"id":"63","span":{"begin":1326,"end":1347},"obj":"Chemical"},{"id":"64","span":{"begin":1373,"end":1381},"obj":"Chemical"},{"id":"65","span":{"begin":1405,"end":1417},"obj":"Chemical"},{"id":"66","span":{"begin":1422,"end":1437},"obj":"Chemical"},{"id":"67","span":{"begin":1471,"end":1481},"obj":"Species"},{"id":"68","span":{"begin":1510,"end":1525},"obj":"Chemical"},{"id":"69","span":{"begin":1582,"end":1592},"obj":"Species"}],"attributes":[{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"Tax:2697049"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"MESH:C578162"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"Tax:88149"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"Tax:2697049"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:9606"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"Gene:59272"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"Gene:59272"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:C000657245"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D006497"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D006497"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:2697049"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D011134"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:88149"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:D011134"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D009844"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:2697049"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Gene:59272"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:C578162"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:2697049"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D006493"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"Tax:2697049"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"Gene:59272"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:D006493"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:C578162"},{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"MESH:C578162"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"Tax:2697049"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D011134"},{"id":"A69","pred":"tao:has_database_id","subj":"69","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.\nThe SARS-CoV-2 spike glycoproteins (SGPs) and human angiotensin converting enzyme 2 (ACE2) are the two key targets for the prevention and treatment of COVID-19. Host cell surface heparan sulfate (HS) is believed to interact with SARS-CoV-2 SGPs to facilitate host cell entry. In the current study, a series of polysaccharides from Saccharina japonica were prepared to investigate the structure-activity relationship on the binding abilities of polysaccharides (oligosaccharides) to pseudotype particles, including SARS-CoV-2 SGPs, and ACE2 using surface plasmon resonance. Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) displayed strongly inhibited interaction between SARS-CoV-2 SGPs and heparin while showing negligible inhibition of the interaction between SARS-CoV-2 SGPs and ACE2. The IC50 values of SJ-D-S-H and Gn in blocking heparin SGP binding were 27 and 231 nM, respectively. NMR analysis showed that the structure of SJ-D-S-H featured with a backbone of 1, 3-linked α-L-Fucp residues sulfated at C4 and C2/C4 and 1, 3-linked α-L-Fucp residues sulfated at C4 and branched with 1, 6-linked β-D-galacto-biose; Gn had a backbone of alternating 1, 4-linked β-D-GlcAp residues and 1, 2-linked α-D-Manp residues. The sulfated galactofucan and glucuronomannan showed strong binding ability to SARS-CoV-2 SGPs, suggesting that these polysaccharides might be good candidates for preventing and/or treating SARS-CoV-2."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":162},"obj":"Sentence"},{"id":"T2","span":{"begin":163,"end":323},"obj":"Sentence"},{"id":"T3","span":{"begin":324,"end":438},"obj":"Sentence"},{"id":"T4","span":{"begin":439,"end":735},"obj":"Sentence"},{"id":"T5","span":{"begin":736,"end":959},"obj":"Sentence"},{"id":"T6","span":{"begin":960,"end":1060},"obj":"Sentence"},{"id":"T7","span":{"begin":1061,"end":1391},"obj":"Sentence"},{"id":"T8","span":{"begin":1392,"end":1593},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.\nThe SARS-CoV-2 spike glycoproteins (SGPs) and human angiotensin converting enzyme 2 (ACE2) are the two key targets for the prevention and treatment of COVID-19. Host cell surface heparan sulfate (HS) is believed to interact with SARS-CoV-2 SGPs to facilitate host cell entry. In the current study, a series of polysaccharides from Saccharina japonica were prepared to investigate the structure-activity relationship on the binding abilities of polysaccharides (oligosaccharides) to pseudotype particles, including SARS-CoV-2 SGPs, and ACE2 using surface plasmon resonance. Sulfated galactofucan (SJ-D-S-H) and glucuronomannan (Gn) displayed strongly inhibited interaction between SARS-CoV-2 SGPs and heparin while showing negligible inhibition of the interaction between SARS-CoV-2 SGPs and ACE2. The IC50 values of SJ-D-S-H and Gn in blocking heparin SGP binding were 27 and 231 nM, respectively. NMR analysis showed that the structure of SJ-D-S-H featured with a backbone of 1, 3-linked α-L-Fucp residues sulfated at C4 and C2/C4 and 1, 3-linked α-L-Fucp residues sulfated at C4 and branched with 1, 6-linked β-D-galacto-biose; Gn had a backbone of alternating 1, 4-linked β-D-GlcAp residues and 1, 2-linked α-D-Manp residues. The sulfated galactofucan and glucuronomannan showed strong binding ability to SARS-CoV-2 SGPs, suggesting that these polysaccharides might be good candidates for preventing and/or treating SARS-CoV-2."}